Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)

NCT00787332 is registered in ClinicalTrials.gov with Canyon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00787332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00787332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)
Lead sponsor
Canyon Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2008
Completion date
December 31, 2009
Enrollment
16 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

suspected heparin-induced thrombocytopenia